Home » Stocks » Avidity Biosciences

Avidity Biosciences, Inc. (RNA)

Stock Price: $29.15 USD -0.41 (-1.39%)
Updated Sep 25, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.09B
Revenue (ttm) 4.99M
Net Income (ttm) n/a
Shares Out 37.53M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 25, 2020
Last Price $29.15
Previous Close $29.56
Change ($) -0.41
Change (%) -1.39%
Day's Open 29.52
Day's Range 27.83 - 30.29
Day's Volume 198,445
52-Week Range 23.06 - 37.46

More Stats

Market Cap 1.09B
Enterprise Value 742.01M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 37.53M
Float 29.25M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 936,760
Short Ratio 5.94
Short % of Float 2.61%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 219.04
PB Ratio 3.36
Revenue 4.99M
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 351.89M
Net Cash / Share 9.38
Gross Margin -244.69%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$43.33*
(48.64% upside)
Low
34.0
Current: $29.15
High
60.0
Target: 43.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018
Revenue2.320.38
Revenue Growth511.87%-
Gross Profit2.320.38
Operating Income-17.33-10.50
Net Income-24.73-11.22
Shares Outstanding2.712.48
Earnings Per Share-9.12-4.53
Operating Cash Flow2.49-9.66
Capital Expenditures-0.24-0.05
Free Cash Flow2.26-9.70
Cash & Equivalents94.583.09
Total Debt4.9410.32
Net Cash / Debt89.64-7.23
Assets96.913.98
Liabilities27.5445.11
Book Value-65.36-41.13
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Avidity Biosciences, Inc.
Country United States
Employees 42
CEO Sarah Boyce

Stock Information

Ticker Symbol RNA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RNA
IPO Date June 12, 2020

Description

Avidity Biosciences, a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of muscle atrophy, duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe diseases. Avidity Biosciences, Inc. was founded in 2012 and is based in La Jolla, California.